AssuredPartners Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

AssuredPartners Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$80K	Sell	10,187 -2,094	-17%	-$10.2K	0.01%	410
2026 Q1	$41.6K	Buy	12,281 +2,262	+23%	+$8.14K	﹤0.01%	401
2025 Q4	$34.3K	Buy	+10,019	New	+$44.7K	0.01%	341
2025 Q2	–	Sell	-15,356	Closed	-$34.2K	–	240
2025 Q1	$34.2K	Buy	+15,356	New	+$44K	0.01%	323

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

AssuredPartners Investment Advisors's ABCL Position: Q2 2026 in Review

AssuredPartners Investment Advisors reduced its AbCellera Biologics (ABCL) stake by 17% in Q2 2026, selling an estimated $10.2K and leaving 10,187 shares worth $80K. The position accounts for 0.01% of the portfolio, ranked #410.

AssuredPartners Investment Advisors first reported a position in ABCL in Q1 2025 and has held it in 4 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

AssuredPartners Investment Advisors held 10,187 shares of AbCellera Biologics worth $80K as of Q2 2026.
AssuredPartners Investment Advisors sold 2,094 AbCellera Biologics shares in Q2 2026, an estimated $10.2K.
AbCellera Biologics made up 0.01% of AssuredPartners Investment Advisors's portfolio in Q2 2026, its #410 holding.
AssuredPartners Investment Advisors first reported a position in AbCellera Biologics in Q1 2025 and has held it in 4 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on AssuredPartners Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.